CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy

OncoImmunology

Volumn 6, Issue 2, 2017, Pages

  Chen, Nan ^a   Morello, Aurore ^a   Tano, Zachary ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adoptive T cell therapy; breast cancer; immunosuppression; lung cancer; mesothelioma; PD 1 blockade; tumor microenvironment

Indexed keywords

CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CELL CYCLE CHECKPOINT; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; HUMAN; NONHUMAN; SOLID TUMOR; TUMOR GROWTH; TUMOR VOLUME;

EID: 85011825145     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1273302     Document Type: Article

References (7)

1. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014; 6:261ra151; PMID:25378643; http://dx.doi.org/10.1126/scitranslmed.3010162
2. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016; 126:3130-44; PMID:27454297; http://dx.doi.org/10.1172/JCI83092
3. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy:mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8:328rv4; PMID:26936508; http://dx.doi.org/10.1126/scitranslmed.aad7118
4. Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016; 76:1578-90; PMID:26979791; http://dx.doi.org/10.1158/0008-5472.CAN-15-2524
5. Rupp L, Schumann K, Roybal KT, Marson A, Lim WA. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. The J Immunol. 2016; 196:214.24; http://www.jimmunol.org/content/196/1_Supplement/214.24
6. Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs:driving T cells to solid tumors. Cancer Discov. 2016; 6:133-46; PMID:26503962; http://dx.doi.org/10.1158/2159-8290.CD-15-0583
7. Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016; 13:143-58; PMID:26598942; http://dx.doi.org/10.1038/nrclinonc.2015.209